title: Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats.
abstract: The 5-HT(3) and 5-HT(4) receptor antagonists alosetron and piboserod, and the muscarinic receptor antagonists PNU-171990A (2-(diisopropylamino)ethyl 1-phenylcyclopentanecarboxylate, hydrochloride) and PNU-174708A (2-(diisopropylamino)ethyl 1-phenylcyclohexanecarboxylate) were studied by electromyography, defining the migrating myoelectric complex (MMC) after i.v. administration in conscious rats. Alosetron prolonged the MMC cycle length from 16.6 to maximally 30.4 min at the dose 0.5 mg kg(-1). Piboserod promptly abolished MMC pattern and prolonged cycle length from 16.5 to >60 min at 0.5 mg kg(-1). PNU-171990A and PNU-174708A had no effect on basal cycle length up to a dose of 20 mg kg(-1). In controls, saline did not change the MMC pattern, while L-hyoscyamine at the same dose, 20 mg kg(-1), prolonged cycle length from 17.6 to 29.0 min. None of the drugs affected duration or propagation velocity of phase III of MMC. Blockade of 5-HT(4) receptors seems to exert a powerful inhibitory effect on motility, 5-HT(3) receptor blockade is less efficient and muscarinic receptor blockade has low efficacy.
authors.affiliation: Section of Gastroenterology and Hepatology, Department of Internal Medicine, Karolinska Hospital, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
authors.forename: Lars Göran
authors.initials: LG
authors.lastname: Axelsson
authors.forename: Berndt
authors.initials: B
authors.lastname: Wallin
authors.forename: Per Göran
authors.initials: PG
authors.lastname: Gillberg
authors.forename: Birger
authors.initials: B
authors.lastname: Sjöberg
authors.forename: Charlotte
authors.initials: C
authors.lastname: Söderberg
authors.forename: Per M
authors.initials: PM
authors.lastname: Hellström
mesh_terms: D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology; D002264:Carboxylic Acids; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D004576:Electromyography; D004952:Esters / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D007421:Intestine, Small / Q000187:drug effects / Q000502:physiology; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D016065:Myoelectric Complex, Migrating / Q000187:drug effects* / Q000502:physiology; D010078:Oxazines / Q000494:pharmacology; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology; D044406:Receptors, Serotonin, 5-HT3 / Q000187:drug effects / Q000502:physiology; D044422:Receptors, Serotonin, 5-HT4 / Q000187:drug effects / Q000502:physiology; D012702:Serotonin Antagonists / Q000494:pharmacology*
chemical_list: C472005:2-(diisopropylamino)ethyl 1-phenylcyclopentanecarboxylate; D002243:Carbolines; D002264:Carboxylic Acids; D003521:Cyclopropanes; D004952:Esters; D007211:Indoles; D018727:Muscarinic Antagonists; D010078:Oxazines; D011976:Receptors, Muscarinic; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists; C090840:alosetron; D044422:Receptors, Serotonin, 5-HT4; C479132:piboserod; D001285:Atropine